ゲノムバイオマーカー市場：製品タイプ、適応疾患、エンドユーザー別-2025-2030年世界予測

ゲノムバイオマーカー市場は、2023年に44億米ドルと評価され、2024年には46億7,000万米ドルに達すると予測され、CAGR 6.67％で成長し、2030年には69億2,000万米ドルに達すると予測されています。

ゲノムバイオマーカーは、生物学的プロセスや反応を測定・評価するために使用されるDNA/RNAシグネチャーであり、個別化された治療アプローチを可能にすることで精密医療を推進する上で極めて重要です。ゲノムバイオマーカーに対するニーズは、慢性疾患の有病率の増加、精密医療研究の急増、個別化ヘルスケアソリューションへのシフトが原動力となっています。これらのバイオマーカーは、個別化医療、疾病診断、創薬開発、リスク評価において重要な用途を見出しています。最終用途は腫瘍学、心臓代謝疾患、神経学、感染症など多岐にわたり、患者の転帰を改善しヘルスケアコストを削減するためのオーダーメイドのヘルスソリューションを提供します。市場の成長は、次世代シーケンサーのような技術的進歩、個別化医療に対する需要の高まり、製薬会社やバイオテクノロジー企業による投資の増加の影響を受けています。また、各国政府も戦略的資金提供や規制の枠組み支援を通じて研究開発を促進しています。しかし、ゲノム技術のコスト高、遺伝子データのプライバシーに関する倫理的懸念、バイオマーカー検証の複雑さといった課題は、市場の成長を阻害する可能性があります。ゲノミクスの絶え間ない進化には、複雑なデータセットを解析するための強固な計算ツールや手法が必要であり、これは重要な技術革新領域です。ゲノムバイオマーカーが最適ながん治療を導くプレシジョン・オンコロジーは、大きな利益をもたらす可能性があります。費用対効果の高いソリューションやポイント・オブ・ケア検査の技術革新の開発にチャンスがあり、バイオテクノロジー企業と学術機関との協力関係を促進することで、臨床導入の迅速化を図ることができます。競合情勢は、技術ポートフォリオと市場リーチを拡大するための合併や戦略的提携の増加傾向を示しています。技術統合に焦点を当て、データプライバシーへの懸念に対処することで、成功への道を切り開くことができます。市場力学はダイナミックで急速に進化しており、イノベーション、規制の変更、ゲノミクスの知識基盤の進歩に後押しされ、バイオ医薬品業界における長期的な持続可能性と競争優位性を目指す投資のための強力なプラットフォームを提供しています。

市場力学：急速に進化するゲノムバイオマーカー市場の主要市場インサイトを公開

ゲノムバイオマーカー市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の早期発見・診断におけるゲノムバイオマーカーの利用拡大
  • 政府および規制当局による調査支援
  • 個別化医療におけるゲノムバイオマーカーの用途拡大
• 市場抑制要因
  • ゲノムバイオマーカー開発に伴う高コストと技術的問題
• 市場機会
  • AIおよび機械学習とゲノム研究の統合
  • 高度な非侵襲性ゲノムバイオマーカー開発への関心の高まり
• 市場の課題
  • ゲノムバイオマーカーの使用に関する倫理的・法的懸念

ポーターのファイブフォース：ゲノムバイオマーカー市場をナビゲートする戦略ツール

ポーターのファイブフォース」フレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ゲノムバイオマーカー市場における外部からの影響の把握

外部マクロ環境要因は、ゲノムバイオマーカー市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ゲノムバイオマーカー市場における競合情勢の把握

ゲノムバイオマーカー市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスゲノムバイオマーカー市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ゲノムバイオマーカー市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ゲノムバイオマーカー市場における成功への道筋を描く

ゲノムバイオマーカー市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の早期発見と診断におけるゲノムバイオマーカーの利用増加
    • ゲノムバイオマーカー調査に対する政府および規制当局の支援
    • 個別化医療におけるゲノムバイオマーカーの応用拡大
  • 抑制要因
    • ゲノムバイオマーカーの開発に伴う高コストと技術的問題
  • 機会
    • AIと機械学習とゲノム研究の統合
    • 高度な非侵襲性ゲノムバイオマーカーの開発への関心の高まり
  • 課題
    • ゲノムバイオマーカーの使用に関する倫理的および法的懸念
• 市場セグメンテーション分析
  • タイプ：医薬品調査における予後バイオマーカーの利用の拡大
  • エンドユーザー：診断センターにおけるゲノムバイオマーカーの応用拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ゲノムバイオマーカー市場：製品別

• 消耗品
• サービス
• ソフトウェア

第7章 ゲノムバイオマーカー市場：タイプ別

• 予測バイオマーカー
• 予後バイオマーカー

第8章 ゲノムバイオマーカー市場：疾患適応症別

• 心血管疾患
• 神経疾患
• 腫瘍学
• 腎疾患

第9章 ゲノムバイオマーカー市場：エンドユーザー別

• 診断センター
• 病院
• 調査機関

第10章 南北アメリカのゲノムバイオマーカー市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のゲノムバイオマーカー市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのゲノムバイオマーカー市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • バイオ・ラッド、乳がん調査の強化に向けた革新的なマルチプレックスデジタルPCRアッセイを発表
  • BiofidelityのASPYRE-Lung RUO試薬による強化された迅速なゲノムバイオマーカー分析のイントロダクション
  • 腫瘍学におけるイルミナの画期的な進歩TruSight Oncology 500 ctDNA v2が固形腫瘍のゲノムプロファイリングを強化
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Agilent Technologies, Inc.
• APIS Assay Technologies Limited
• Augurex Life Sciences Corp
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Biocrates Life Sciences AG
• Biostarks Laboratories SA
• Bruker Corporation
• CD Genomics
• Charles River Laboratories, Inc.
• DH Life Sciences, LLC.
• Elo Health, Inc.
• Eurofins Scientific corporation
• F. Hoffmann-La Roche Ltd
• Illumina Inc.
• Merck KGaA
• Myriad Genetics, Inc
• Owkin, Inc
• Thermo Fisher Scientific company

LIST OF FIGURES

• FIGURE 1. GENOMIC BIOMARKER MARKET RESEARCH PROCESS
• FIGURE 2. GENOMIC BIOMARKER MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GENOMIC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. GENOMIC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. GENOMIC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GENOMIC BIOMARKER MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GENOMIC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GENOMIC BIOMARKER MARKET DYNAMICS
• TABLE 7. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RENAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. CANADA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. CANADA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. CANADA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. CHINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. CHINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CHINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 61. CHINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. INDIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. INDIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. INDIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. INDIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. ITALY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. ITALY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ITALY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 134. ITALY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. POLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. POLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. POLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 150. POLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. QATAR GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. QATAR GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. QATAR GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 154. QATAR GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. GENOMIC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. GENOMIC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2023

The Genomic Biomarker Market was valued at USD 4.40 billion in 2023, expected to reach USD 4.67 billion in 2024, and is projected to grow at a CAGR of 6.67%, to USD 6.92 billion by 2030.

Genomic biomarkers are DNA/RNA signatures used to measure and evaluate biological processes or responses, pivotal in driving precision medicine advances by enabling individualized therapeutic approaches. The need for genomic biomarkers is driven by the increasing prevalence of chronic diseases, a surge in precision medicine research, and the shifts towards personalized healthcare solutions. These biomarkers find significant applications in personalized medicine, disease diagnosis, drug discovery and development, and risk assessment. Their end-use spans across oncology, cardio-metabolic disorders, neurology, and infectious diseases, providing tailored health solutions to improve patient outcomes and reduce healthcare costs. Market growth is influenced by technological advancements like next-gen sequencing, rising demand for personalized medicine, and increased investments by pharmaceutical and biotech companies. Governments are also fostering R&D through strategic funding and supportive regulatory frameworks. However, challenges such as high costs of genomic technologies, ethical concerns related to genetic data privacy, and the complexity of biomarker validation may hinder market growth. The constant evolution of genomics necessitates robust computational tools and methodologies to analyze complex datasets, representing a significant innovation area. Precision oncology can benefit greatly, where genomic biomarkers guide optimal cancer therapies. Opportunities lie in developing cost-effective solutions and point-of-care testing innovations, encouraging collaborations between biotech firms and academic institutions to expedite clinical implementations. The competitive landscape shows an increasing trend of mergers and strategic alliances to broaden technology portfolios and market reach. Focusing on technology integration and addressing data privacy concerns can forge a successful path forward. The nature of the genomic biomarker market is dynamic and rapidly evolving, driven by innovation, regulatory changes, and the progressing knowledge base in genomics, providing a potent platform for investments aiming at long-term sustainability and competitive advantage in the biopharmaceutical industry.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Genomic Biomarker Market

The Genomic Biomarker Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing usage of genomic biomarkers in early detection and diagnosis of chronic disease
  • Governments and regulatory support for genomic biomarker research
  • Growing applications of genomic biomarkers in personalized medicine
• Market Restraints
  • High cost and technical issues associated with developing genomic biomarkers
• Market Opportunities
  • Integration of AI and machine learning with genomic studies
  • Growing interest in developing advanced noninvasive genomic biomarkers
• Market Challenges
  • Ethical and legal concerns regarding the use of genomic biomarkers

Porter's Five Forces: A Strategic Tool for Navigating the Genomic Biomarker Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Genomic Biomarker Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Genomic Biomarker Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Genomic Biomarker Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Genomic Biomarker Market

A detailed market share analysis in the Genomic Biomarker Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Genomic Biomarker Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Genomic Biomarker Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Genomic Biomarker Market

A strategic analysis of the Genomic Biomarker Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Genomic Biomarker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocrates Life Sciences AG, Biostarks Laboratories SA, Bruker Corporation, CD Genomics, Charles River Laboratories, Inc., DH Life Sciences, LLC., Elo Health, Inc., Eurofins Scientific corporation, F. Hoffmann-La Roche Ltd, Illumina Inc., Merck KGaA, Myriad Genetics, Inc, Owkin, Inc, and Thermo Fisher Scientific company.

Market Segmentation & Coverage

This research report categorizes the Genomic Biomarker Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Consumables, Services, and Software.
• Based on Type, market is studied across Predictive Biomarkers and Prognostic Biomarkers.
• Based on Disease Indication, market is studied across Cardiovascular Diseases, Neurological Diseases, Oncology, and Renal Disorders.
• Based on End-User, market is studied across Diagnostic Centers, Hospitals, and Research Institutions.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing usage of genomic biomarkers in early detection and diagnosis of chronic disease
    • 5.1.1.2. Governments and regulatory support for genomic biomarker research
    • 5.1.1.3. Growing applications of genomic biomarkers in personalized medicine
  • 5.1.2. Restraints
    • 5.1.2.1. High cost and technical issues associated with developing genomic biomarkers
  • 5.1.3. Opportunities
    • 5.1.3.1. Integration of AI and machine learning with genomic studies
    • 5.1.3.2. Growing interest in developing advanced noninvasive genomic biomarkers
  • 5.1.4. Challenges
    • 5.1.4.1. Ethical and legal concerns regarding the use of genomic biomarkers
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Proliferating use of prognostic biomarkers in pharmaceutical research
  • 5.2.2. End-user: Expanding application of genomic biomarkers in diagnostic centers
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Genomic Biomarker Market, by Product

• 6.1. Introduction
• 6.2. Consumables
• 6.3. Services
• 6.4. Software

7. Genomic Biomarker Market, by Type

• 7.1. Introduction
• 7.2. Predictive Biomarkers
• 7.3. Prognostic Biomarkers

8. Genomic Biomarker Market, by Disease Indication

• 8.1. Introduction
• 8.2. Cardiovascular Diseases
• 8.3. Neurological Diseases
• 8.4. Oncology
• 8.5. Renal Disorders

9. Genomic Biomarker Market, by End-User

• 9.1. Introduction
• 9.2. Diagnostic Centers
• 9.3. Hospitals
• 9.4. Research Institutions

10. Americas Genomic Biomarker Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Genomic Biomarker Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Genomic Biomarker Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Bio-Rad Introduces Revolutionary Multiplexed Digital PCR Assay for Enhanced Breast Cancer Research
  • 13.3.2. Biofidelity's Introduction ASPYRE-Lung RUO Reagents for Enhanced and Rapid Genomic Biomarker Analysis
  • 13.3.3. Illumina's Breakthrough in Oncology TruSight Oncology 500 ctDNA v2 Enhances Solid Tumor Genomic Profiling
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies, Inc.
• 3. APIS Assay Technologies Limited
• 4. Augurex Life Sciences Corp
• 5. Bio-Rad Laboratories, Inc.
• 6. Bio-Techne Corporation
• 7. Biocrates Life Sciences AG
• 8. Biostarks Laboratories SA
• 9. Bruker Corporation
• 10. CD Genomics
• 11. Charles River Laboratories, Inc.
• 12. DH Life Sciences, LLC.
• 13. Elo Health, Inc.
• 14. Eurofins Scientific corporation
• 15. F. Hoffmann-La Roche Ltd
• 16. Illumina Inc.
• 17. Merck KGaA
• 18. Myriad Genetics, Inc
• 19. Owkin, Inc
• 20. Thermo Fisher Scientific company